Core Viewpoint - Hangzhou Shenluo Medical Technology Co., Ltd. has completed a multi-hundred million RMB Series C financing round, led by Junlian Capital, with participation from existing shareholders including OrbiMed, Boyuan Capital, and Guotou Chuanghe [2]. Company Introduction - Hangzhou Shenluo Medical Technology Co., Ltd. is engaged in the research and development of medical devices related to neuroregulation and brain-computer interfaces, headquartered in Hangzhou, Zhejiang Province [2]. Product and Technology Overview - The company focuses on the development and commercialization of implantable neurostimulation devices and brain-computer interface technologies [2]. 1. **Spinal Cord Stimulation (SCS) System**: Approved by the National Medical Products Administration (NMPA) for chronic pain management, launched in early 2026 [2]. 2. **Peripheral Nerve Stimulation (PNS) System**: Currently in the registration application stage for peripheral nerve regulation treatments [3]. 3. **Tibial Nerve Stimulation (TNS) System**: Targets neuroregulation for urinary function-related diseases, part of the company's wireless micro-neuroregulation technology platform [4]. 4. **Brain-Computer Interface Technology**: Developing a closed-loop brain-computer interface system for applications in neural function recovery, including spinal cord injuries [7]. 5. **Sublingual Nerve Stimulation System**: Under development for the treatment of obstructive sleep apnea [8]. Product Registration Status - The company has received multiple medical device registration certificates from the National Medical Products Administration, including: - Spinal Cord Stimulation External Controller - Implantable Spinal Cord Stimulation Electrodes - Test Stimulator - Patient Controller for Spinal Cord Stimulation [9]. Financing History - The financing history includes: - March 2026: Series C round, amount undisclosed, led by Chengdu Junrongkang Venture Capital [10]. - April 2024: Series B+ round, multi-hundred million RMB, led by OrbiMed [10]. - October 2022: Series B round, approximately hundred million RMB, led by Guotou Chuanghe [10]. - January 2022: Series A round, multi-million RMB, led by Bodin Capital [10]. Patent Situation - The company holds several authorized patents related to neurostimulation devices and methods, including: - Manufacturing methods for stimulation electrodes - Control methods for electrical stimulation devices - Wireless power supply devices for neurostimulators [12].